Literature DB >> 24300883

Trends of hepatitis B notification rates in Turkey, 1990 to 2012.

P Ay1, M A Torunoglu, S Com, Z Çipil, S Mollahaliloğlu, Y Erkoc, U Dilmen.   

Abstract

Turkey is a country with intermediate endemicity for hepatitis B, and approximately 4% of the population are HBsAg-positive. A number of measures have been implemented to prevent hepatitis B infection. In 1998, hepatitis B antigen was included in the national immunisation programme, and infants have since been vaccinated with three doses. Catch-up strategies, vaccination for high risk groups and screening measures were also adopted. The aim of this study was to evaluate the impact of the prevention and control strategies on hepatitis B notification rates in Turkey in the period from 1990 to 2012, using data from the national surveillance system. Secular trends revealed that rates showed an initial increasing trend, followed by a steady decline from 2005. The most dramatic decline occurred among children younger than 15 years, highlighting the benefits of vaccination and catch-up strategies. However, vaccination cannot fully explain the decrease in this age group. Socioeconomic development, through interrupting the horizontal transmission may also have contributed. After 2005, a steady decline was achieved also among those 15 years and older. The rates in adults were higher, which indicates that stronger prevention measures are needed to target this group, particularly men.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24300883     DOI: 10.2807/1560-7917.es2013.18.47.20636

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  9 in total

1.  Antithrombin as a marker of severe acute hepatitis B.

Authors:  Simona Arientová; O Beran; P Chalupa; M Kořínková; M Holub
Journal:  Indian J Gastroenterol       Date:  2019-05-14

2.  Trends of acute hepatitis B notification rates in eastern China from 2005 to 2013.

Authors:  Zhifang Wang; Yaping Chen; Jinren Pan
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

3.  Analysis of Knowledge, Attitudes, and Prevalence of Hepatitis B and C Seromarkers Among Barbers in Tehran.

Authors:  Tahereh Khairkhah; Ayat Shamsa; Azam Roohi; Jalal Khoshnoodi; Vand Fatemeh Rajabpour; Mina Tabrizi; Saeed Zarei; Forough Golsaz-Shirazi; Fazel Shokri
Journal:  Hepat Mon       Date:  2016-08-13       Impact factor: 0.660

4.  Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.

Authors:  Alessandro Miglietta; Chantal Quinten; Pier Luigi Lopalco; Erika Duffell
Journal:  Euro Surveill       Date:  2018-02

5.  Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening.

Authors:  Özgür M Koc; Niel Hens; Rob Bielen; Pierre Van Damme; Geert Robaeys
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Are men who have sex with men in Europe protected from hepatitis B?

Authors:  M Brandl; A J Schmidt; U Marcus; M An der Heiden; S Dudareva
Journal:  Epidemiol Infect       Date:  2020-02-13       Impact factor: 2.451

Review 7.  Epidemiological Profile of Hepatitis B Virus Infection in Iran in the Past 25 years; A Systematic Review and Meta-analysis of General Population Studies.

Authors:  Zahra Mohammadi; Abbasali Keshtkar; Sareh Eghtesad; Alireza Jeddian; Ali Akbar Pourfatholah; Mahtab Maghsudlu; Maryam Zadsar; Zahra Mahmoudi; Amaneh Shayanrad; Hossein Poustchi; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2016-01

8.  Prevalence of HBV, HCV and HIV in Inpatients of a Mental Health Hospital in Turkey, 2011-2013.

Authors:  Nuran Karabulut
Journal:  Iran J Public Health       Date:  2015-07       Impact factor: 1.429

9.  Infectious disease testing of UK-bound refugees: a population-based, cross-sectional study.

Authors:  Alison F Crawshaw; Manish Pareek; John Were; Steffen Schillinger; Olga Gorbacheva; Kolitha P Wickramage; Sema Mandal; Valerie Delpech; Noel Gill; Hilary Kirkbride; Dominik Zenner
Journal:  BMC Med       Date:  2018-08-28       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.